Helicobacter pylori: ¿Cómo tratarla en América Latina en el 2019?
Palabras clave:
Helicobacter, antibióticos, resistencia, terapias.Resumen
La Helicobacter pylori (H.pylori), infecta al 60% de la población mundial. Con la amplia utilización de antibióticos para múltiples enfermedades, el microorganismo cada día ha desarrollado resistencia a los mismos. En Latinoamérica, hay alta prevalencia los antibióticos más frecuentemente utilizados. En la presente revisión narrativa, se discuten los aspectos básicos de los esquemas de erradicación, destacando la importancia de la adecuada supresión del ácido clorhídrico cuando se utilicen antibióticos pH dependientes. Así mismo, se dan recomendaciones para erradicar la infección en Latinoamérica. Se discute que faltan estudios para poder recomendar los probióticos como adyuvantes a las terapias actuales.
Descargas
Citas
Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-analysis Gastroenterology 2017, DOI: http://dx.doi.org/10.1053/j.gastro.2017.04.022 on line april 27.
O´Coonor A, O´Morain CA, Ford CA. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2017;on line march 20.
Malfertheiner P, Megraud F, O´Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Mangement of Helicobacter pylori infection:The Maastricht V/Florence Consensus Report. Gut 2017;66:6-30.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212-39.
Fallone CA, Chiba N, van Zanten SV. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016;151:51-59.
Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, et al. IV conferencia española de consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol 2016;39:697-721.
Sugano K, Tack J, Kuipers EJ. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-67.
IARC Helicobacter pylori Working Group 2014. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8). Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
Nam JH, Hong CW, Kim BC, Shin A, Ryu KH, Park BJ, et al. Helicobacter pylori infection is an independent risk factor for colonic adenomatous neoplasms. Causes Control. 2017;28(2):107-115.
Rokkas T, Gisbert JP, Niv Y, O'Morain C. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterol J. 2015;3(6):539-50.
Rokkas, T., Pistiolas, D., Sechopoulos, P., Robotis I, Margantinis, G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta- analysis. Clin Gastroenterol Hepatol 2007;5: 1413–1417.
Moayyedi, P. et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120–1126.
Saad, A. M., Choudhary, A. & Bechtold, M. L. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol 2012; 47:129–135.
Neumeister P, Troppan K, Raderer M,. Management of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Dig Dis 2015;33:11–18
Scott D, Weeks D, Melchers K. The life and death of Helicobacter pylori. Gut 1998;43 (Suppl 1):S56-S60.
Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5:321-331.
Yonezawa H, Osaki T, Kamiya S. Biofilm Formation by Helicobacter pylori and its involvement for antibiotic resistance. Biomed Res Int 2015;2015:914791.
Wang YH, LV ZF, Zhong Y, Liu DS, Chen SP. The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication. Helicobacter 2017; 22: e12324; DOI: 10.1111/hel.12324.
Malfertheiner P, Selgrad M. Helicobacter pylori. Curr Opin Gastroenterol 2014; 30:589-95.
Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H.pylori eradication therapies. Helicobacter 2017;e12392,DOI:10.1111/hel.12392.
Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther 2016;14:577-85.
Shiotani A, Lu H, Dore MP:, Graham DY. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Clev Clin J Med 2017; 84:30-8.
Villoria A, García P, Calvet X, Gisbert J, Vergara M. Meta-analysis: high dose proton pump inhibtor vs standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008;28:868-77.
Ducoumau A, Bénéjat L, Sifré LE, Lehours P, Mégraud F. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin Microbiol Infect 2016;22:715-8.
Thung I, Aramin RH, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514–533.
Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernández –García T, et al. The problema of Helicobacter pylori resistance to antibotics: a systematic review in Latin America. Am J Gastroenterol 2014; 109:485-495.
OMS 2017.
Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.Aliment Pharmacol Ther 2012;35:209–221.
Furuta T, Graham DY. Pharmacologic aspects of eradicaction therapy for Helicobacter pylori infection. Gastroenterol Clin North Am 2010; 39:465-80.
Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichilkawa H, et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol 2013; 54:258-66.
Bayerdorffer E, Miehlike S, Mannes GA. Double bind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108:1412-7.
Zullo A, Ridola L, Francesco VD, et al. High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015; 28:448–451.
Sapmaz F, Kalkan IH, Atasoy P, Basyigit S, Guliter S. A non-inferiority study: modified dual therapy consisting higher doses of rabeprazole is as successful as standard quadruple therapy in eradication of Helicobacter pylori. Am J Ther. 2015; [Epub ahead of print].
Murakami M, Sakurai Y, Shiino M, Funao N, Nisimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016;65:1439–1446.
Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, Imai R. More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Can J Gastroenterol Hepatol 2017, Article ID 4385161, doi.org/10.1155/2017/4385161.
Arévalo A, Trespalacios AA, Otero W, manuscrito sometido a publicación.
Isaza C, Henao J, Isaza Martínez JH, Sepúlveda JC, Beltrán L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clinical Pharmacol 2007;7:6.
Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther 2015; 42:922-33.
Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016; 65:870-8.
Sun Q, Liang X, Zheng Q. High efficacy of 14 –day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15:233-8.
Otero W, manuscrito en preparación.
Cao Z, Chen Q, Zhang W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol 2015; 50:1185–90.
Gisbert JP, Romano M, Gravina AG, Solis-Muñoz P, Bermejo F, Molina-Infante J, et al. Helicobacter pylori second–line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015; 41:768-75.
Otero W, Manuscrito en preparación.
Otero W, Trespalacios AA, Otero L, Vallejo M, Torres M, Pardo R, Sabbagh LC. Guía práctica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Col Gastroenterol 2015; 30(Suppl. 1):17-33.
Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather that medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12:177-86.
Gisbert JP. Enfermedades relacionadas con la infección por Helicobacter pylori. Gastroenterol Hepatol 2014;37 (Supl. 3):42-52.
Graham DY, Fagoonee Pellicano R. Increasing role for modified bismuth containing quadruple therapies for Helicobacter pylori eradication. Minerva Gatroenterol Dietol 2017;63:77-9.
Lu H, Zhang W, Graham DY. Bismuth containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepato 2013;25:1134-40).
Otero W, Gutiérrez O, Saabagh LC: Efectiveness of a hibrid therapy in eradicating Helicobacter pylori in a Colombian population. Gastroenterology 2016; 150:S246.
Graham DY, Laine L. The Toronto Helicobacter pylori consensus. Gastroenterology 2016; 151:9-12.
Park CS, Lee SM, Park CH, Koh HR, Jun CH, Park SY, et al. Pretreatment Antimicrobial Susceptibility-Guided Vs. Clarithromycin-Based Triple Therapy for Helicobacter pylori Eradication in a Region with High Rates of Multiple Drug Resistance. Am J Gastroenterol 2014;109(10):1595-602.
Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, Xu B, Liu M, Chen Y, Sun Y, Zhao Y, Xu G, Song Y, Yu L, Zhang W, Liu W, Graham DY, Lu H. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49(11):1385-1394
Arévalo A, Trespalacios AA, Otero W, 2017, manuscrito sometido a publicación.
Trespalacios-RangélAA,, Otero W, Arévalo-Galvis A, Raúl A. Poutou-Piñales R, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá- Colombia (2009-2014). PLOS ONE | DOI:10.1371/journal.pone.0160007 July 25, 2016 1 /.
Cheng H, HU FL.Furazolidone , amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol 2009;15:860-64.
Matsumoto H, Shiotani A, Graham DY. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol. 2019, april 24,. doi: 10.1007/5584_2019_367.
Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol. 2012;18:1–2.
Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013;25:1134–1140.
Segura AM, Gutiérrez O, Otero W, Angel LA, Genta R, Graham DY. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11:529-32.
Otero W, Gutierrez O, Sierra F. Erradicación de H pylori con Terapia Triple: Bismuto, Furazolidona, Tetraciclina. Acta Med Col. 1996;21:218, (Res).
Hong L, Zhang W, Graham DY. Bismuth–containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013;25:1134-40.
Cheng H, HU FL.Furazolidone , amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol 2009;15:860-64.
Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-metronidazole-and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802-7.
Zullo A, Ierandi E, Hassan C. De Francesco V. Furazolidona-based terapies for Helicobacter pylori infection: a pooled data analysis. Saudi J Gastroenterol 2012;18:11-7.
Some food additives, feed additives and naturally acurring substances. IARC Monogra Eval Carcinog Risk Chem Hum 1983;31:1-291.
Some food additives, feed additives and naturally acurring substances. IARC Monogra Eval Carcinog Risk Chem Hum 1983;31:1-291.
Auro A, Sumano H, Ocampo L, Barragán A. Evaluation the carcinogenic effects of furazolidone and its metabolites in two fish species. Pharmacogenomics J 2004;4:24-8.
Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.Aliment Pharmacol Ther 2012;35:209–221.
Ciccaglione AF, Tavani R, Grossi L, et al. Rifabutin containing triple therapy and rifabutin with bismuth Containing quadruple therapy for third-line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter 2016;21: 375–381.
Ono S, Kato M, Nakagaewa S. Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a régimen consiting of clarithromycin and metronidazole in patients ellergic to penicillin. Helicobacter 2017;e12374,DOI:10.1111/hel.12374.
Hill C, Guarner F, Reid G. Expert Consensus document: The international Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use on the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-14.
Manfredi M, Bizzarri B, Sacchero RI, et al. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics and lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter 2012;17:254–263.
Shavakhi A, Tabesh E, Yaghoutkar A, et al. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. Helicobacter 2013;18:280–284.
Lau CS, Ward A, Chamberlain RS. Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis. Infect Drug Resist. 2016;9:275–289. Published 2016 Dec 7. doi:10.2147/IDR.S117886
Molina-Infante J, Gisbert JP. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time. Rev Esp Enferm Dig 2013;105:441–444.
Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J Gastroenterol 2015; 21: 4345-4357.
Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: A meta-analysis. PLoS One. 2014;9:e111030.
McFarland LV, Huang Y, Wang L, Malrtheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunvant therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur Gastroenterol J 2016;4:546-51.
Graham DY. Editorial--Avoiding Unethical Helicobacter pylori Clinical Trials: Susceptibility-Based Studies and Probiotics as Adjuvants. Helicobacter. 2015;20(5):321–325. doi:10.1111/hel.12244
López-Góngora S, Puig I, Calvet I, Villoria A, Baylina M, Muñoz N, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother doi:10.1093/jac/dkv155.
Liou JM, Chen CC, Chang CC, Cheng MJ, Hsu SJ, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicenter clinical trial. J Antimicrob Chemother 2013; 68:450–456.
Puig I, López-Góngora S, Calvet X, Villoria A, Baylina M, Sánchez-Delgado J, et al. Systematic review: third-line susceptibility guided treatment for Helicobacter pylori . Ther Adv Gastroenterol 2016; 9: 437–48.
Gisbert JP, Gisbert JL, Marcos S, Jiménez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10 year single center study of 500 patients. Aliment Pharmacol Ther 2008;27, 346–354.
Costa S, Soares JB, Goncalves R. Efficacy and tolerability of culture-guiaded treatment for Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2017; early rel Sept 6, DOI 10.1097/MEG.0000000000000960.
Lee JY, Kim N. Diagnosis of Helicobacter pylori by invasive test: histology . Ann Transl Med 2015;3(1):10.
Descargas
Cómo citar
Número
Sección
Licencia
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y construir a partir del material
- para cualquier propósito, incluso comercialmente.
Bajo los siguientes términos:
-
Atribución — Usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
- No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
